Please login to the form below

Not currently logged in
Email:
Password:

Diabetes costs increase for NHS

Drugs to treat diabetes cost the NHS in England £725m in 2010/11, an increase of 41.1 per cent from the 2005/06 period

Drugs to treat diabetes cost the NHS in England £725m in 2010/11, an increase of 41.1 per cent from the 2005/06 period.

Diabetes prescriptions now account for 8.4 per cent of the NHS bill for primary care drugs, compared to 6.6 per cent in 2005/06, according to a report from the NHS Information Centre,

This follows an increase in diagnosed incidents of diabetes in England, increasing from 1.89 million people in 2005/06 to 2.34 million people in 2009/10. This is 4.3 per cent of the country's population.

The total number of items prescribed was also up significantly in the five-year period, increasing 41.2 per cent to 38.3 million.

Of these items, 14.6 million were prescriptions for metformin, a drug used in the treatment of type 2 diabetes. Prescriptions for the drug increased 70.1 per cent from 2005/06 to 2010/11, due primarily to its recommendation from the National Institute for Health and Clinical Excellence (NICE) as the first choice drug for oral therapy in type 2 diabetes.

Tim Straughan, chief executive at the NHS Information Centre, said: “This information will help people and health professionals see the impact that caring for diabetes has on NHS prescribing; and support the NHS in planning for how to best address the condition moving forward.”

The report is available from the NHS Information Centre: www.ic.nhs.uk/pubs/prescribingfordiabetes05-11

24th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics